178306-51-9

Usage

Uses

Used in Pharmaceutical Industry:
Dexibuprofen is utilized as an analgesic and anti-inflammatory agent for the treatment of conditions such as arthritis, menstrual cramps, and minor aches and pains. Its efficacy in reducing discomfort and swelling is attributed to its inhibitory action on the enzymes responsible for the production of inflammatory substances.
Used in Pain Management:
Dexibuprofen serves as a pain reliever, addressing a wide range of painful conditions by mitigating the inflammatory processes that contribute to pain sensation. This makes it a common choice for both acute and chronic pain management under the supervision of healthcare professionals.
Used in Inflammation Reduction:
Beyond its analgesic properties, dexibuprofen is also used to reduce inflammation. Its ability to inhibit key enzymes involved in inflammation makes it suitable for conditions characterized by excessive inflammation, such as certain types of arthritis.
Formulations:
Dexibuprofen is available in various pharmaceutical formulations to cater to different patient needs and preferences. These include tablets, capsules, and oral suspensions, allowing for flexible and convenient administration of the medication.
Precautions:
Like other NSAIDs, dexibuprofen may have potential side effects, including gastrointestinal issues and an increased risk of cardiovascular events. Therefore, its use should be approached with caution and under the guidance of a healthcare professional to ensure safe and effective treatment.

InChI:InChI=1/C16H16O4/c1-20-16(14(17)15(18)19,12-8-4-2-5-9-12)13-10-6-3-7-11-13/h2-11,14,17H,1H3,(H,18,19)

Upstream product

• 178306-52-0 (S)-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid 
• 178306-47-3 2-hydroxy-3-methoxy-3,3-diphenylpropionicacid methyl ester 
• 119-61-9 benzophenone 
• 124-41-4 sodium methylate 
• 96-34-4 methyl chloroacetate 
• 177036-94-1 ambrisentan 
• 76527-25-8 3,3-diphenyloxirane-2-carboxylic acid methyl ester 

Downstream Products

• 177036-78-1 (S)-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid methyl ester 
• 204268-09-7 (S)-3-<2-(3,4-dimethoxyphenyl)ethoxy>-2-hydroxy-3,3-diphenylpropionic acid methyl ester 
• 204268-10-0 (S)-3-<2-(3,4-dimethoxyphenyl)ethoxy>-2-hydroxy-3,3-diphenylpropionic acid 
• 204267-33-4 Feloprentan 
• 171714-84-4 darusentan 
• 1106685-61-3 (S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropionic acid methyl ester 
• 177036-79-2 (S)-methyl 2-(4,6-dimethoxypyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionate 
• 1231755-36-4 (S)-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid tertiary butylamine salt 
• 1231755-40-0 (S)-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid dicyclohexylamine R(+)-phenylethylamine 
• 178306-59-7 benzyl 3-methoxy-2-((4-methoxy-6,7-dihydro-5H-cyclopentapyridin-2-yl)oxy)-3,3-diphenylpropionate 
• 178306-52-0 (S)-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid 
• 177036-94-1 ambrisentan 
• 1240470-84-1 (S)-methyl-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionate 
• 178306-47-3 2-hydroxy-3-methoxy-3,3-diphenylpropionicacid methyl ester 

Relevant academic research and scientific papers

Synthesis method of 2-hydroxy-3-methoxy-3, 3-diphenyl propionic acid

The invention relates to a synthetic method of 2-hydroxy-3-methoxy-3, 3-diphenyl propionic acid. The invention relates to a preparation method of an ambrisentan key intermediate 2-hydroxy-3-methoxy-3,3-diphenyl propionic acid. According to the preparation

METHOD FOR PRODUCING (S)-2-HYDROXYPROPANOIC ACID DERIVATIVE

PROBLEM TO BE SOLVED: To provide a method for producing an (S)-2-hydroxypropanoic acid derivative and ambrisentan having high optical purity in an industrially advantageous manner. SOLUTION: There is provided a method for producing an (S)-2-hydroxypropanoic acid derivative represented by the formula (1a) by reacting an (RS)-2-hydroxypropanoic acid derivative represented by the formula (1) with (S)-(+)-1,2,3,4-tetrahydro-1-naphthylamine to form a diastereomer salt, followed by desalting. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Process for Preparing Ambrisentan

The present invention relates to a method of preparing high purity ambrisentan in a cost-effective and efficient way, and a novel intermediate product used for the method. According to the present invention, optical resolution of 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid can be cost-effectively and efficiently performed using L-prolinamide, and thus crystalline ambrisentan having 99.9% or more of purity and optical purity can be prepared on an industrial scale using the same.COPYRIGHT KIPO 2016

New carboxylic acid derivative, its production and its use

Heterocyclyl-substd. propanoic acids and their derivs., of formula (I), are new. R = formyl, tetrazolyl, nitrile, COOH or a gp. that can be hydrolysed to COOH; X = N or CR14; R2 = H, OH, NH2, alkylamino, dialkylamino, halo, alkyl, haloalkyl, alkoxy, haloalkoxy or alkylthio; R14 = H or 1-5 C alkyl; R3 = R2 or alkoxyimino; or CR3 + CR14 = 5 or 6 membered alkylene or alkenyl ring (opt. substd. by 1-2 alkyl) in which a methylene can be replaced by O, S, NH or alkylamino; R4, R5 = phenyl or naphthyl (both opt. substd. by one or more halo, NO2, CN, OH, alkyl, haloalkyl, alkoxy, haloalkyloxy, phenoxy, alkylthio, NH2, alkylamine or dialkylamino) or 3-7 C cycloalkyl; or the phenyl or naphthyl gps. are opt. bonded at the O- position (by a bond, CH2, O, S, SO2, ethylene, ethenylene or opt. alkylated amino); R6 = H, 1-8 C alkyl, 2-6 C alkenyl, 3-6 C alkynyl, 3-8 C cycloalkyl (all opt. substd. by 1 or more halo, NO2, CN, alkoxy 3-6 C alkenyloxy, 3-6 C alkynyloxy, alkylthio, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, 3-8 C alkylcarbonylalkyl, alkylamino, dialkylamino, phenyl, Ph or OPh), Ar or Het; Y = S, O or bond; Q = S, O, SO, SO2 or bond; Ph = substd. phenyl, where substits. are halo, NO2, CN, alkyl, haloalkyl, alkoxy, haloalkoxy or alkylthio; Ar = phenyl or naphthyl (both opt. substd. by 1 or more halo, NO2, CN, OH, NH2, alkylamino, dialkylamino or OCH2CH2O); Het = 5 or 6 membered heteroaromatic with 1-3 N atoms and/or one S or O (opt. substd. by 1-4 halo and/or 1 or 2 alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, phenyl, phenoxy or phenyl carbonyl (where the phenyl is opt. substd. by 1-5 halo and/or 1-3 alkyl, haloalkyl, alkoxy, haloalkoxy and/or alkylthio)); alkyl and alkoxy have 1-4 C unless otherwise stated; provided that R6 is not H when Q = bond.

LC-MS/MS characterization of forced degradation products of ambrisentan: Development and validation of a stability-indicating RP-HPLC method

The current study reports the characterization of degradation products of ambrisentan by liquid chromatography-tandem mass spectrometry, and development and validation of a stability-indicating reversed phase high performance liquid chromatographic method

IMPROVED PROCESS TO PREPARE S-2-HYDROXY-3-METHOXY-3,3-DIPHENYL PROPIONIC ACID

Disclosed is a process for the preparation of S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (I) the key intermediate for the preparation of Ambrisentan [(+)-2(S)-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid]. Ambrisentan of the formula (IA) is approved under the trademark "Letairis " by the US Food and Drug Administration for the treatment of Pulmonary artery hypertension(PAH).

Improved Process For The Preparation Of Endothelin Receptor Antagonists

The present invention relates to improved processes for the preparation of Endothelin receptor antagonists, their salts and intermediates.

IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS

The present invention relates to improved processes for the preparation of Endothelin receptor antagonists, their salts and intermediates.

Biocatalytic racemization of (hetero)aryl-aliphatic α- hydroxycarboxylic acids by Lactobacillus spp. proceeds via an oxidation-reduction sequence

The biocatalytic racemization of a range of (hetero)aryl- and (di)aryl-aliphatic α-hydroxycarboxylic acids has been achieved by using whole resting cells of Lactobacillus spp. The essentially mild (physiological) reaction conditions ensure the suppression of undesired side reactions, such as elimination, decomposition or condensation. Cofactor/inhibitor studies using a cell-free extract of Lactobacillus paracasei DSM 20207 reveal that the addition of redox cofactors (NAD+/NADH) leads to a distinct increase in the racemization rate, while strong inhibition is observed in the presence of Thio-NAD+, which suggests that the racemization proceeds by an oxidation-reduction sequence rather than involvement of a "racemase" enzyme. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.

Structural similarity and its surprises: Endothelin receptor antagonists -process research and development report

Process research and pilot plant processes are described for three endothelin (ET) receptor antagonists. The efficient synthesis of the parent compound Darusentan proceeds via a Darzens reaction from chloroacetate with benzophenone, addition of methanol to the resulting epoxide, saponification of the alkyl propionate and optical resolution of the racemic acid by crystallisation with a chiral amine. The final stage of the synthetic sequence involves the introduction of a pyrimidine moiety. Intermediates formed during this process can be used as starting materials for the synthesis of the two other ET receptor antagonists BSF 420627 and BSF 302146. An ether exchange reaction, which replaces the methoxy with a phenethyloxy substituent, enabled BSF 420627 to be prepared. The synthetic route to BSF 302146 employs trimethylaluminum to methylate the epoxide produced by the Darzens reaction.